| Aurobindo
Pharma Ltd., has registered a total income of Rs.1,214
crores (Rs.1,052
crs) for the year ended
31st March 2003, registering a
growth of 15%.
During
the period, EBDITA stood at Rs.205.86 crs (Rs.137.04 crs)
registering a growth of 50%.
After taking into account interest of Rs.42.59
crs (Rs.42.39 crs), depreciation of Rs.23.18 crs
(Rs.15.81 crs) and provision for taxation of Rs.36.95
crs (Rs.20.33 crs), the net profit for the year stood at
Rs.103.14 crs (Rs.68.51 crs), registering a growth of
50%.
The
above figures are not comparable to that of last year
as the fourth quarter figures include the merged
entities, Ranit Pharma, Calac and one time income item
of Rs.12.43 crores.
The
Company’s exports for the year amounted to Rs.579.30
crs (Rs. 495.18 crs) comprising 49% of the total sales.
The Net worth of the Company stands at Rs.535.53 crs
(Rs.361.77 crs).
The
consolidated total income for the year stood at
Rs.1,362.16 crs (Rs.1,181.49 crs) and the net profit
stood at Rs.86.94 crs (Rs.73.09 crs). Most of the joint
ventures and subsidiaries are in the initial operations
phase wherein expenses are written off reflecting in
lower consolidated profit.
|
PRESS
ROOM 
